Carol Bentley

Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked

N. Curtin, D. Newell, Lan Z. Wang, 2008, Cell cycle.

Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy.

B. Cornelissen, A. Banham, M. Cragg, 2017, Cancer research.

Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodies

A. Banham, Demin Li, Carol Bentley, 2017, PloS one.

Context-Dependent Cell Cycle Checkpoint Abrogation by a Novel Kinase Inhibitor

N. Foloppe, A. Massey, Jenifer Borgognoni, 2010, PloS one.

Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy

A. Harris, A. Banham, P. Handford, 2019, Molecular Cancer Therapeutics.

Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A*0201

A. Banham, F. Pezzella, Demin Li, 2021, PloS one.